Abstract
Coronavirus disease 2019(COVID 19) is an illness caused by novel corona virus which is now known as SARS-CoV-2. This disease has become a global pandemic as a large population worldwide is suffering from it. Due to this reason, researchers have conducted clinical trials for some potential drugs like hydroxychloroquine, favipiravir, remdesivir, lopinavir-ritonavir, Dexamethasone and Tocilizumab. Hydroxychloroquine which was previously used to treat rheumatoid arthritis, when taken in combination with azithromycin has shown to prevent SARS-CoV-2 in some cases. Faviravir which was previously used to treat influenza and ebola virus has shown promising results. Remdesivir is a broad spectrum antiviral drug has also emerged as a potential drug but further information is required to verify its effects. Lopinavirritonavir is an anti-HIV drug. Both of them are protease inhibitor, as a result this drug is beneficial for treating COVID 19. Dexamethasone is a corticosteroid drug previously used to treat rheumatic conditions, has shown to prevent SARSCoV2. Tocilizumab is a immunosuppressant drug which blocks IL6 and used to prevent COVID 19.Itolizumab was previously used for treating psoriasis, has showed positive results in treating SARS-CoV-2. This article shows a comparative study of the different drugs which has entered the clinical trials.
Recommended Citation
Roy, Debshikha Dutta; Roy, Sohini; and Talukder, Pratik
(2024)
"Covid 19 medicines: Drugs which entered clinical trial,"
American Journal of Applied Bio-Technology Research (AJABTR): Vol. 1, Article 4.
Available at:
https://research.smartsociety.org/ajabtr/vol1/iss3/4